HomeDiscoveryCongressi ed eventiCongressi ed eventi 2010

Congressi ed eventi 2010

2010

Novembre 16-19
EORTC-NCI-AACR
Berlin, Germany
Web link
Abstract
Pharmacological characterization of NMS-P506, a novel second generation HSP90 inhibitor
S. Mantegani, N. Amboldi, A. De Ponti, L. Gianellini, M. Guanci, M. Paolucci, D. Donati, E. Pesenti, A. Isacchi
Abstract
NMS-P118, a Parp-1 selective inhibitor with efficacy in DNA repair deficient tumor models
A. Montagnoli, S. Rainoldi, F. Sola, H. Posteri, R. Lupi, E. Pesenti, D. Donati, J. Moll, D. Pezzetta, G. Papeo
Abstract
Activity of the Cdc7 inhibitor NMS-1116354 as single agent and in combination in breast cancer models
A. Montagnoli, D. Ballinari, A. Ciavolella, S. Rainoldi, M. Menichincheri, E. Pesenti, A. Galvani, A. Isacchi, J. Moll
Abstract
Identification and preclinical characterization of NMS-P626, a potent, selective and orally bioavailable TrkA inhibitor with anti-tumor activity in a TrkA-dependent colorectal cancer
E. Ardini, A. Lombardi Borgia, C. De Ponti, N. Amboldi, D. Ballinari, M.B. Saccardo, P. Magnaghi, E. Pesenti, A. Isacchi, A. Galvani
Abstract
NMS-E628, a potent and orally available small molecule inhibitor of Anaplastic Lymphoma Kinase, reduces tumor growth in an intracranial model of ALK-dependent NSCLC
E. Ardini, M. Menichincheri, P. Magnaghi, C. De Ponti, N. Amboldi, A. Degrassi, M. Russo, P. Orsini, E. Pesenti, A. Galvani

Ottobre 6-8
MASSA
Milano, IT
Web link
Oral presentation
Setup of a Flow Injection Method for the Study of Non-Covalent Interaction on Biopolymers
F. Riccardi Sirtori

Settembre 29-Ottobre 2
XXVIII Conferenza Nazionale di Citometria
Urbino, IT
Web link
Oral presentation
Click chemistry" e analoghi della BrdU: nuove strategie nello studio della sintesi del DNA
P. Cappella

Settembre 29-30
Optimizing Early Phase Oncology Studies to Accelerate Proof of Concept
Brussels, Belgium
Web link
Oral presentation
Case Studies from Nerviano Medical Sciences: Planning and Implementing FIH Studies
S. Crippa

27-28 Settembre 2010
NIH CTEP Meeting
Bethesda, USA
Web link
Oral Presentation
Preclinical characterization of ALK inhibitor NMS-E628 in ALCL and NSCLC tumor models
A. Galvani

Settembre 21-22
Innovation in Phase I clinical development
Munich, Germany
Web link
Oral presentation
Resistance mechanisms of targeted therapies
J. Moll

Settembre 21-22
ESSCA 2010
Valencia, Spain
Web link
Oral presentation
BrdU versus "Click chemistry" : new opportunitis for DNA synthesis in flow and image cytometry
P. Cappella

Settembre 12-16
NMMC 2010 - XX National Meeting on Medicinal Chemistry
Abano Terme, IT
Web link
Oral presentation
Development of pyrazolo-quinazolines as CDK inhibitors: identification of PHA-848125, a potent, orally available compound
MG. Brasca
Abstract
Identification of N-{6,6-DIMETHYL-5-[(1-METHYLPIPERIDIN-4-YL)CARBONYL]-1,4,5,6-TETRAHYDRO PYRROLO[3,4-c]PYRAZOL-3-YL}-3-METHYLBUTANAMIDE, a potent CDK inhibitor suitable for intravenous dosing
P.Orsini

Settembre 5-9
XXIst International Symposium on Medicinal Chemistry
Brussels, Belgium
Web link
Abstract
Cdc7 kinase inhibitors: 2-heteroaryl-3-carboxamido-5-aryl pyrroles as potential anticancer agents
M. Menichincheri

Agosto 22-26
ACS
Boston, US
Web link
Abstract
Benzo[d]imidazole/indole inhibitors of coactivator associated argininemethyltransferase 1 (CARM1)
H. Wan, T. Huynh, S. Pang, J. Geng, T. Bandiera, S. Bindi, P. Vianello, F. Roletto, S. Thieffine, A. Galvani, W. Vaccaro, M. A Poss, G. L Trainor, M. V. Lorenzi, M. Gottardis, L. Jayaraman, A.V. Purandare

Luglio 21
Italian MRI/MRS Users' Meeting
Torino, IT
Web link
Oral presentation
"In vivo" homing of labelled neural stem cells in a mouse model of spinal cord injury
A. Degrassi

Luglio 8-10
Secondo Congresso Nazionale di Bioingegneria
Torino, IT
Web link
Abstract 60
Quantitative evaluation of the Aurora inhibitor effect on gene and protein expression: a mathematical modelling approach
N. Terranova, R. Bosotti, Carpinelli P, G.Galli, M Bertolotti, P. Magni

Giugno, 21-23
Next generation kinase inhibitors - Oncology and Beyond
Cambridge, MA
Web link
Oral presentation
Mitotic spindle kinase inhibitors to target aneuploid cancer cells.
J. Moll
Oral presentation
New trends and opportunities in kinase inhibitors design.
F. Zuccotto

Giugno, 8-9
The 5th annual cell-based assays conference
Cologne
Web link
Oral presentation
Cell-based profiling and screening assays for protein kinases.
F. Gasparri

Giugno 4-8
ASCO
Chicago, US
Web link
Abstract 2087
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in recurrent malignant glioma (MG).
A. Benouaich-Amiel, E. Mazza, C. Massard, P. Gaviani, F. Fiorentini, A. Scaburri, M.A. Pacciarini, E. Calvo
Abstract 3063
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 in combination with gemcitabine in advanced solid tumors.
R. Bahleda, A. Spreafico, J. C. Soria, C. Moldovan, C. Belli, F. Fiorentini, A. Scaburri, M.A. Pacciarini, B. L'affranchi, M. Reni
Abstract 3065
Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.
S. Cresta, C. Sessa, G. Del Conte, A. Locatelli, E. Gallerani, F. Fiorentini, A. Scaburri, M. A. Pacciarini, R. Alzani, L. Gianni
Abstract 3066
Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
P.J. Rosen, A.W. Tolcher, P. Lee, M. Smitley, M. Fuerst, R. Spinelli, S. Crippa, M.G. Jannuzzo, S. Comis, K. Papadopoulos
Abstract 5014
Phase II study of danusertib in advanced/ metastatic breast and ovarian cancers.
C. Sessa, E. Gallerani, J.P. Delord, P. Schöffski, I. Vergote, V. Trillet-Lenoir, M. Maur, M.G. Jannuzzo, A. Petroccione, G. Locatelli, D. Lorusso

Maggio, 26-27
Targeted Cancer Therapies
London, EN
Web link
Oral presentation
Cancer Cell Specificity for Cell Cycle Inhibitors - a Paradox or an Opportunity?
J. Moll

Maggio, 16-20
28th Camerino-Cyprus-Noordwijkerhout Symposium
Camerino, IT
Web link
Oral presentation
G protein coupled receptors: old landscape with new eyes.
D. Donati

Aprile 17-21
AACR
Washington, US
Web link
Abstract 691
In vitro and in vivo characterization of a selective orally available PARP-1 inhibitor with anti-tumor efficacy in BRCA negative cancer models.
G. Papeo, S. Rainoldi, L.. Gianellini, A. Ciavolella, E. Corti, A. Leone, R. Lupi, F. Sola, F. Caprera, M. Paolucci, R. Perego, C. Albanese, E. Casale, B. Forte, M. Guanci, P. Orsini, H. Posteri, A. Scolaro, F. Riccardi-Sirtori, F. Zuccotto, D. Pezzetta, D. Donati, J. Moll, A. Montagnoli
Abstract 2522
Identification and characterization of new highly selective and potent BRAF inhibitors.
M. Pulici, N. Amboldi, S. Biondaro, F. Caprera, E. Casale, F. Gasparri, A. Leone, R. Lupi, C. Marzoionni, M. Modugno, W. Pastori, G. Traquandi, F. Zuccotto, F. Colotta, D. Donati, E. R. Felder, A. Galvani, A. Isacchi, E. Pesenti, M. Ciomei
Oral presentation
NMS-1116354: more than an inhibitor of Cdc7 kinase in S-phase.
F. Colotta

Marzo, 4-6
TAT
Bethesda, US
Web link
Oral presentation
Danusertib, a pan-aurora kinase inhibitor: Clinical review.
B. Laffranchi

Febbraio 11-12
Screening Europe
Barcelona, SP
Web link
Oral presentation
MPS-1 kinase inhibition in cancer cells: the fast track to cell death.
J. Moll

Febbraio 4-5
Risonanza Magnetica in Medicina
Milano, IT
Web link
Oral presentation
MRI and PET evaluation of disease progression and efficacy of a cell cycle inhibitor on a lung adenocarcinoma transgenic mouse model.
A. Degrassi